KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Equity Average (2016 - 2025)

Historic Equity Average for Fulgent Genetics (FLGT) over the last 10 years, with Q3 2025 value amounting to $1.1 billion.

  • Fulgent Genetics' Equity Average fell 93.99% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 93.99%. This contributed to the annual value of $1.1 billion for FY2024, which is 567.95% down from last year.
  • Per Fulgent Genetics' latest filing, its Equity Average stood at $1.1 billion for Q3 2025, which was down 93.99% from $1.1 billion recorded in Q2 2025.
  • Fulgent Genetics' 5-year Equity Average high stood at $1.3 billion for Q2 2022, and its period low was $685.5 million during Q1 2021.
  • In the last 5 years, Fulgent Genetics' Equity Average had a median value of $1.1 billion in 2024 and averaged $1.1 billion.
  • In the last 5 years, Fulgent Genetics' Equity Average soared by 92264.7% in 2021 and then plummeted by 1092.91% in 2024.
  • Fulgent Genetics' Equity Average (Quarter) stood at $1.1 billion in 2021, then rose by 15.42% to $1.3 billion in 2022, then decreased by 6.01% to $1.2 billion in 2023, then decreased by 5.41% to $1.1 billion in 2024, then dropped by 1.13% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.1 billion for Q2 2025, and $1.1 billion during Q1 2025.